Real-Time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors with Actionable Mutations

The UVA Cancer Center is doing a clinical research study in patients who have lung cancer where their tumor has a certain kind of mutation. Patients with these types of cancer may be receiving a type of oral drug called a tyrosine kinase inhibitor, or TKI, and the researchers want to learn more about some of the side effects that they may experience. To do this, they’ve developed a system for researchers to check in and patients to report side effects and related issues on their smartphones.

A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have early stage cervical cancer that will be treated with surgery. The purpose of this study is to investigate if minimally invasive surgery, called robotic assisted laparoscopy (small incision surgery), is worse than open surgery (otherwise known as a laparotomy) when performing a radical hysterectomy for cervical cancer.

Patients with recurrent and/or metastatic head and neck cancer with high-risk HPV16 infection are needed for a study to research an investigative therapy in combination with immunotherapy

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and recurrent and/or metastatic head and neck cancer with high risk HPV16 infection. The purpose of this study to evaluate the combination of an investigational drug (PDS0101) and an immunotherapy drug (pembrolizumab) in patients with high risk HPV16 positive head and neck cancer. The effects of the investigational and immunotherapy drug combination will be evaluated for this study.

Phase 3 randomized study of datopotamab deruxtecan (DS-1062A) versus docetaxel in previously treated advanced non-small cell lung cancer without actionable genomic alterations (TROPION-LUNG01)

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have non-small cell lung cancer without mutations. The purpose of this study to evaluate an investigational drug (DS-1062A) compared to a chemotherapy drug (docetaxel) in patients with non-small cell lung cancer. The safety and effects of the investigational drug will be evaluated for this study.

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The University of Virginia Comprehensive Cancer Center seeks adult patients ages 18 and over with relapsed or refractory B-Cell Non-Hodgkins Lymphoma(NHL) for a research study. This study consists of two parts (phase 1a and phase 1b). You are being asked to participate in phase 1a. This part of the study is being conducted to find the maximum tolerated dose of a new investigational drug, KT413 (study drug).

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have

A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have advanced solid tumors whose disease has progressed despite standard treatments. If you join this study, you will receive an investigational drug called ZX-4081. The purpose of this research is to learn more about the safety of ZX-4081 at different dose levels and to find the highest tolerable dose that can be safely given to patients with advanced solid tumors, and to recommend a dose to be used in future studies.

Discussion Sessions For Dementia Caregivers

The Department of Neurology is conducting a research study for adults who provide care for a loved one with memory or thinking problems. The purpose of the study is to evaluate a method of teaching caregivers about memory loss and dementia.

In the study, you will attend six 1.5-hour weekly group sessions online or in-person where you will be taught ways to better navigate caregiving. You will also answer questionnaires a few times throughout the study about yourself and the person to whom you give care.

Study-related activities are provided at no cost.

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 75 and over who have newly diagnosed Diffuse Large B cell Lymphoma (DLBCL). This study will look at the effects of the combination of two drugs: an investigational chemotherapy drug + standard drug therapy. The goal is to see if this approach is better than standard of care.

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

The University of Virginia Cancer Center seeks adults age 18 or older with diffuse large B-cell lymphoma for a research study. Brentuximab vedotin has been approved for treatment of certain diseases, but the purpose of the study is to see how well brentuximab vedotin, lenalidomide, and rituximab work together in treating diffuse large b-cell lymphoma and what side effects it causes.

You may be eligible for this study if: your diffuse large B-cell lymphoma has come back or did not get better with your last treatment.

Subscribe to